Green Tea catchins as Neuroprotective Agents: Systematic Review of the Literature in Animal Pre-clinical trials

Lisa Dufy, Paul Roach, Nenad NAUMOVSKI

Research output: Contribution to journalArticle

11 Downloads (Pure)

Abstract

Alzheimer's Disease (AD) is a neurodegenerative disorder and the most common form of dementia, with symptoms and manifestations that progressively get worse with increasing age. Therefore, with the ageing of the population worldwide, the prevalence of AD is increasing. There is no current cure for AD and, as a result, there has been a recent rise in interest in plant bioactive compounds that may prevent or improve symptoms of the disease. Currently, the nootropic potential of plant derived compounds that can combat damage posed by free radicals is being investigated. Antioxidants, in particular, the Green Tea Catechins (GTC), have been shown significant interest due to their exceptionally strong antioxidant and anti-inflammatory properties. The aim of this paper was to perform a systematic review based on the PRISMA guidelines in order to evaluate the effectiveness of GTC as a potential treatment to suppress or delay the onset of AD in pre-clinical animal trials. The paper reports on three animal pre-clinical trials in which rat or mice models of AD were used to test the effects of GTC or the pure form of the predominant GTC, Epigallocatechin gallate (EGCG), administered orally or by injection. The reviewed papers show that GTC extracts or pure EGCG had preventative effects on AD in the various animal models used, including the enhancement of learning and memory, possibly through the reduction in oxidative stress, β-amyloid plaque build up and Tau protein phosphorylation. Therefore, GTC extracts or EGCG in its pure form may serve as nootropic options in the prevention or treatment of neurodegeneration-associated diseases such as AD.
Original languageEnglish
Pages (from-to)48-57
Number of pages10
JournalAdvances in Food Technology and Nutrition Sciences
Volume1
Issue number2
DOIs
Publication statusPublished - 2015

Fingerprint

Neuroprotective Agents
Tea
Alzheimer Disease
Clinical Trials
Catechin
Nootropic Agents
Antioxidants
tau Proteins
Amyloid Plaques
Phytochemicals
Neurodegenerative Diseases
Free Radicals
Dementia
Oxidative Stress
Anti-Inflammatory Agents
Animal Models
Phosphorylation
Learning
Guidelines
Injections

Cite this

@article{bdf67bf2af2d4c99992512b1b50c80b5,
title = "Green Tea catchins as Neuroprotective Agents: Systematic Review of the Literature in Animal Pre-clinical trials",
abstract = "Alzheimer's Disease (AD) is a neurodegenerative disorder and the most common form of dementia, with symptoms and manifestations that progressively get worse with increasing age. Therefore, with the ageing of the population worldwide, the prevalence of AD is increasing. There is no current cure for AD and, as a result, there has been a recent rise in interest in plant bioactive compounds that may prevent or improve symptoms of the disease. Currently, the nootropic potential of plant derived compounds that can combat damage posed by free radicals is being investigated. Antioxidants, in particular, the Green Tea Catechins (GTC), have been shown significant interest due to their exceptionally strong antioxidant and anti-inflammatory properties. The aim of this paper was to perform a systematic review based on the PRISMA guidelines in order to evaluate the effectiveness of GTC as a potential treatment to suppress or delay the onset of AD in pre-clinical animal trials. The paper reports on three animal pre-clinical trials in which rat or mice models of AD were used to test the effects of GTC or the pure form of the predominant GTC, Epigallocatechin gallate (EGCG), administered orally or by injection. The reviewed papers show that GTC extracts or pure EGCG had preventative effects on AD in the various animal models used, including the enhancement of learning and memory, possibly through the reduction in oxidative stress, β-amyloid plaque build up and Tau protein phosphorylation. Therefore, GTC extracts or EGCG in its pure form may serve as nootropic options in the prevention or treatment of neurodegeneration-associated diseases such as AD.",
keywords = "Green Tea catechins, EGCG, Antioxidant, Alzheimer's Disease, Neuroprotection",
author = "Lisa Dufy and Paul Roach and Nenad NAUMOVSKI",
year = "2015",
doi = "10.17140/AFTNSOJ-1-108",
language = "English",
volume = "1",
pages = "48--57",
journal = "Advances in Food Technology and Nutrition Sciences",
issn = "2377-8350",
number = "2",

}

TY - JOUR

T1 - Green Tea catchins as Neuroprotective Agents: Systematic Review of the Literature in Animal Pre-clinical trials

AU - Dufy, Lisa

AU - Roach, Paul

AU - NAUMOVSKI, Nenad

PY - 2015

Y1 - 2015

N2 - Alzheimer's Disease (AD) is a neurodegenerative disorder and the most common form of dementia, with symptoms and manifestations that progressively get worse with increasing age. Therefore, with the ageing of the population worldwide, the prevalence of AD is increasing. There is no current cure for AD and, as a result, there has been a recent rise in interest in plant bioactive compounds that may prevent or improve symptoms of the disease. Currently, the nootropic potential of plant derived compounds that can combat damage posed by free radicals is being investigated. Antioxidants, in particular, the Green Tea Catechins (GTC), have been shown significant interest due to their exceptionally strong antioxidant and anti-inflammatory properties. The aim of this paper was to perform a systematic review based on the PRISMA guidelines in order to evaluate the effectiveness of GTC as a potential treatment to suppress or delay the onset of AD in pre-clinical animal trials. The paper reports on three animal pre-clinical trials in which rat or mice models of AD were used to test the effects of GTC or the pure form of the predominant GTC, Epigallocatechin gallate (EGCG), administered orally or by injection. The reviewed papers show that GTC extracts or pure EGCG had preventative effects on AD in the various animal models used, including the enhancement of learning and memory, possibly through the reduction in oxidative stress, β-amyloid plaque build up and Tau protein phosphorylation. Therefore, GTC extracts or EGCG in its pure form may serve as nootropic options in the prevention or treatment of neurodegeneration-associated diseases such as AD.

AB - Alzheimer's Disease (AD) is a neurodegenerative disorder and the most common form of dementia, with symptoms and manifestations that progressively get worse with increasing age. Therefore, with the ageing of the population worldwide, the prevalence of AD is increasing. There is no current cure for AD and, as a result, there has been a recent rise in interest in plant bioactive compounds that may prevent or improve symptoms of the disease. Currently, the nootropic potential of plant derived compounds that can combat damage posed by free radicals is being investigated. Antioxidants, in particular, the Green Tea Catechins (GTC), have been shown significant interest due to their exceptionally strong antioxidant and anti-inflammatory properties. The aim of this paper was to perform a systematic review based on the PRISMA guidelines in order to evaluate the effectiveness of GTC as a potential treatment to suppress or delay the onset of AD in pre-clinical animal trials. The paper reports on three animal pre-clinical trials in which rat or mice models of AD were used to test the effects of GTC or the pure form of the predominant GTC, Epigallocatechin gallate (EGCG), administered orally or by injection. The reviewed papers show that GTC extracts or pure EGCG had preventative effects on AD in the various animal models used, including the enhancement of learning and memory, possibly through the reduction in oxidative stress, β-amyloid plaque build up and Tau protein phosphorylation. Therefore, GTC extracts or EGCG in its pure form may serve as nootropic options in the prevention or treatment of neurodegeneration-associated diseases such as AD.

KW - Green Tea catechins

KW - EGCG

KW - Antioxidant

KW - Alzheimer's Disease

KW - Neuroprotection

UR - http://www.mendeley.com/research/green-tea-catechins-neuroprotective-agents-systematic-review-literature-animal-preclinical-trials

U2 - 10.17140/AFTNSOJ-1-108

DO - 10.17140/AFTNSOJ-1-108

M3 - Article

VL - 1

SP - 48

EP - 57

JO - Advances in Food Technology and Nutrition Sciences

JF - Advances in Food Technology and Nutrition Sciences

SN - 2377-8350

IS - 2

ER -